Please wait...
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
Uptravi (selexipag) lowers blood pressure in your lungs by dilating (widening) blood vessels that supply blood to the lungs.
Uptravi is used to treat pulmonary arterial hypertension (PAH).
Uptravi helps keep your condition from getting worse and helps lower your risk of needing to be hospitalized for PAH.
Tell your doctor about all your current medicines and any you start or stop using. Many drugs can interact, and some drugs should not be used together.
You should not use Uptravi if you are allergic to selexipag.
Many drugs can interact and cause dangerous effects. Some drugs should not be used together with selexipag. Your doctor may change your treatment plan if you also use:
clopidogrel; or
gemfibrozil.
To make sure Uptravi is safe for you, tell your doctor if you have ever had:
a condition called pulmonary veno-occlusive disease (narrowing of the veins that carry blood from the lungs to the heart); or
liver disease.
It is not known whether selexipag will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
You should not breastfeed while using Uptravi.
Take Uptravi exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose.
You may take this medicine with or without food.
Swallow the tablet whole and do not crush, chew, or break the tablet.
You should not stop taking Uptravi without your doctor's advice. Stopping suddenly may make your condition worse.
Store at room temperature away from moisture and heat.
Usual Adult Dose for Pulmonary Hypertension:
Initial dose: 200 mcg orally twice a day
Maintenance dose: Increase in increments of 200 mcg orally twice a day at weekly intervals to the highest tolerated dose
Maximum dose: 1600 mcg orally twice a day
Comment:
-If the patient reaches a dose that is not well tolerated, reduce to a previously tolerated dose.
Use: For the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization for PAH
Use the medicine as soon as you can, but skip the missed dose if your next dose is due in less than 6 hours. Do not use two doses at one time.
If you miss doses or forget to take Uptravi for 3 or more days, call your doctor before taking another dose. You may need to restart the medicine at a lower dose than you took before.
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Get emergency medical help if you have signs of an allergic reaction to Uptravi: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or
new lung problems--anxiety, sweating, pale skin, severe shortness of breath, wheezing, gasping for breath, cough with foamy mucus, chest pain, fast or uneven heart rate.
Common Uptravi side effects may include:
headache;
jaw pain;
muscle pain, pain in your arms or legs;
nausea, vomiting, diarrhea; or
flushing (warmth, redness, or tingly feeling).
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.
Other drugs may interact with selexipag, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Uptravi only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Uptravi (www.drugs.com/uptravi.html).
Note: This document contains side effect information about selexipag. Some of the dosage forms listed on this page may not apply to the brand name Uptravi.
Common side effects of Uptravi include: diarrhea, headache, jaw pain, limb pain, myalgia, nausea, vomiting, and flushing. Other side effects include: anemia, and decreased appetite. See below for a comprehensive list of adverse effects.
Applies to selexipag: oral tablet
Along with its needed effects, selexipag (the active ingredient contained in Uptravi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking selexipag:
Incidence not known
Some side effects of selexipag may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
Applies to selexipag: oral tablet
The most frequently reported side effects included headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing.
Very common (10% or more): Headache (up to 65%)
Frequency not reported: Burning sensation
Very common (10% or more): Diarrhea (up to 42%), nausea (up to 34%), vomiting (up to 18%)
Common (1% to 10%): Abdominal pain, dyspepsia, abdominal discomfort
Frequency not reported: Ascites
Very common (10% or more): Jaw pain (26%), pain in extremity (up to 17%), myalgia (up to 16%), arthralgia (up to 11%)
Common (1% to 10%): Musculoskeletal pain, neck pain
Frequency not reported: Bone pain
Very common (10% or more): Flushing (up to 12%), sinus tachycardia (up to 11.3%)
Common (1% to 10%): Hypotension
Frequency not reported: Hot flush
Very common (10% or more): Rash (11%)
Common (1% to 10%): Urticaria, erythema
Very common (10% or more): Nasopharyngitis (13%)
Common (1% to 10%): Nasal congestion
Frequency not reported: Pulmonary veno-occlusive disease
Common (1% to 10%): Hyperthyroidism, thyroid stimulating hormone decreased
Common (1% to 10%): Anemia, hemoglobin decreased
Common (1% to 10%): Appetite decreased
Common (1% to 10%): Eye pain, retinal disorder
Common (1% to 10%): Malignancy
Common (1% to 10%): Asthenia, pyrexia, pain, influenza, weight decreased
Frequency not reported: Acute renal failure
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Uptravi (www.drugs.com/uptravi.html).
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
